YCBD cbdMD, Inc.
Perfumes, Cosmetics & Other Toilet Preparations · NYSE · SEC CIK 1644903 · Fiscal year ends 09/30
Financial factors as of 2026-06-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY10.0%
TTM net income YoY-90.8%
TTM EPS YoY—
Revenue 3-yr CAGR-7.3%
Net income 3-yr CAGR—
Margins
Gross margin57.7%
Operating margin-13.9%
Net margin-13.8%
FCF margin-11.5%
EBITDA margin-12.8%
Returns
ROE-40.3%
ROA-25.1%
ROIC (approx.)-41.2%
Asset turnover1.82x
Leverage & solvency
Liabilities / assets37.5%
Debt / equity0.00x
Current ratio2.50x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.77x
Accruals ratio-5.8%
Payout ratio—
Capex / revenue0.9%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-09-30 | FY20242024-09-30 |
|---|---|---|
| Income statement | ||
| Revenue | $19.19M | $19.48M |
| Cost of revenue | $7.22M | $7.49M |
| Gross profit | $11.97M | $12.00M |
| Operating income | -$2.16M | -$3.32M |
| Pretax income | -$2.04M | -$3.70M |
| Income tax | $0 | $0 |
| Net income | -$2.04M | -$3.70M |
| EBITDA | -$1.80M | -$2.86M |
| EPS (basic) | -1.09 | -14.29 |
| EPS (diluted) | -1.09 | -14.29 |
| Weighted avg. shares (diluted) | 4.02M | 539,069 |
| Banking | ||
| Net interest income | $34,308 | -$29,507 |
| Balance sheet | ||
| Cash & equivalents | $2.26M | $2.45M |
| Receivables | $786,449 | $621,678 |
| Inventory | $2.95M | $2.52M |
| Current assets | $6.55M | $6.39M |
| PP&E, net | $277,377 | $454,268 |
| Goodwill | $0 | — |
| Intangibles | $2.12M | $2.89M |
| Total assets | $10.42M | $10.58M |
| Current liabilities | $3.19M | $8.62M |
| Total liabilities | $3.19M | $8.62M |
| Shareholders' equity | $7.23M | $1.96M |
| Shares outstanding | 8.92M | 492,383 |
| Cash flow statement | ||
| Operating cash flow | -$1.45M | -$352,792 |
| Capital expenditure | $184,172 | $190,015 |
| Free cash flow | -$1.64M | -$542,807 |
| Investing cash flow | -$184,172 | -$290,015 |
| Financing cash flow | $1.45M | $1.30M |
| Depreciation & amortization | $361,063 | $452,326 |
Free plan shows the latest 2 periods; Pro shows all 10 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.